MorphoSys to Host Conference Call on License Agreement with Emergent to Co-Develop and Commercialize Prostate Cancer Drug Candidate MOR209/ES414

        Print
| Source: MorphoSys AG

MARTINSRIED / MUNICH, Germany, Aug. 20, 2014 (GLOBE NEWSWIRE) -- On 19 August 2014, MorphoSys and Emergent BioSolutions Inc. announced an agreement for the joint development and commercialization of MOR209/ES414. The compound is a bi-specific antibody targeting prostate cancer.

Today, 20 August 2014, at 2:00 p.m. CEST (8:00am EDT, 1:00pm BST), the Management Board of MorphoSys AG will host a public conference call and webcast to present more information on the transaction.

Dial-in number for the Conference Call (listen-only):

Germany:                    +49 (0) 89 2444 32975

For U.K. residents:      +44 (0) 20 3003 2666

For U.S. residents:      +1 202 204 1514

MorphoSys offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com.

An audio replay and manuscripts of the conference will be available on www.morphosys.com/conference-calls in due course.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Conference Call Alert http://hugin.info/130295/R/1849893/645803.pdf

HUG#1849893